DX&VX入選2024年韓國首個ARPA-H項目，專攻室溫和超長期疫苗儲存技術
引領韓國ARPA-H項目：聚焦mRNA疫苗室溫儲存和超長期保存 為mRNA疫苗的長期室溫儲存和高效配…
水滴金融母公司CEO沈鵬：將進一步發展國際化業務 分享數字化服務能力
北京2024年11月1日 /美通社/ — 10月28日，以「點亮金融科技新航道」為主題的…
美通社
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
HONG KONG, Nov. 1, 2024 /PRNewswire/ — Akeso Biopharma is pleased to announce the successful enrollment of the first patient in the AK112-309 trial, a randomized, controlled, multicenter Phase III registration study for biliary track tumor. This trial is designed to compare the ivonescimab combined regimen, a PD-1/VEGF bispecific
美國全國綜合癌症網絡與越南國家癌症醫院攜手合作，提升癌症治療水平
國際合作在越南會議上，旨在促進治療建議指南的制定，以幫助癌症患者改善生活質量。 越南河內2024年1…
National Comprehensive Cancer Network Joins with Vietnam National Cancer Hospital to Enhance Cancer Treatment
International collaboration meets in Vietnam to facilitate treatment recommendation guidelines that help people with cancer to live better lives. HANOI, Vietnam, Nov. 1, 2024 /PRNewswire/ — As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National Comprehensive Cancer Network® —an alliance of leading
HKBN Appoints Dr Gabriel Leung as Chief Executive Officer – Enterprise Solutions
HONG KONG, Nov. 1, 2024 /PRNewswire/ — HKBN Group is excited to announce the appointment of Dr Gabriel Shing-Koon Leung as Chief Executive Officer – Enterprise Solutions. Dr Leung will lead the Group’s Enterprise Solutions strategy, enhancing its competitive advantage to accelerate